Viking Therapeutics Inc Phase 2 VENTURE Trial of VK2735 Results Call Transcript
Hello, and welcome to the Viking Therapeutics Phase two venture study Top Line Data Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q&A session to ask a question. At that time, please press the star key followed by one on your touchtone phone. Again, that is star one. If anyone has difficulty hearing the conference, please press star zero for OPERATOR assistance. As a reminder, this conference call is being recorded today, February 27th, 2024. And now I would like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO, Marianne Mancini, the Company's Chief Operating Officer, and Greg Zante, Viking's Chief Financial Officer.
Before we begin, I'd like to caution that comments made during this conference call today, February 27, 2024, will
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |